EUCTR2013-004139-62-ES进行中（未招募）不适用
A pilot open-label, phase II, single-arm study to evaluatethe association of biomarkers of hormonal resistance andthe mTOR pathway with the clinical efficacy of everolimusplus letrozole in the first line treatment of postmenopausalwomen with hormone positive metastatic or locallyadvanced breast cancer
ovartis Farmacéutica S. A.0 个研究点开始时间: 2013年11月12日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Patient signed informed consent both for study and sample cession. Written informed consent must be obtained before any trial related activity and according to local guidelines.
- •2. Post-menopausal women (>18 years of age) with metastatic or locally advanced unresectable disease. The patients must be treatment-naïve for advanced disease, although any agent is permitted during the adjuvant/neoadjuvant treatment.
- •3. Disease relapses at any time, during or after adjuvant therapy
- •4. Histopathological confirmation of hormone-receptor positive (estrogen-receptor positive (ER+) or progesterone receptor positive (PR+), defined as positivity of 10% in either of the receptors) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer.
- •5. Ductal or lobular breast cancer are allowed.
- •6. Available paraffin tumor sample at the time of diagnosis. Histologic confirmation of the disease site is also recommendable. In that case, if sufficient material is available after diagnosis, the sample should be sent to the sponsor.
- •7. Postmenopausal women. Postmenopausal status is defined either by:
- •a. Age >55 years and one year or more of amenorrhea
- •b. Age < 55 years and one year or more of amenorrhea, with an estradiol assay <20pg/ml
- •c. Surgical menopause with bilateral oophorectomy
- •d. Note: Ovarian radiation or treatment with a luteinizing hormone-release hormone (LHRH) agonist (goserelin acetate or leuprolide acetate) is not permitted for induction of ovarian suppression
- •8. No prior treatment for metastatic/advanced breast cancer.
- •9. Patients must either have at least one lesion that can be accurately measured in at least one dimension >20mm with conventional imaging techniques or >10mm with spiral CT or evaluable disease defined as bone lesions: lytic or mixed (lytic plus sclerotic) in the absence of measurable disease as defined above
- •10. Adequate bone marrow and coagulation function as shown by:
- •a. Absolute neutrophil count (ANC) >1.5x109/L
- •b. Platelets >100x109/L
- •c. Hemoglobin (Hgb) >9.0g/dL
- •11. Adequate liver function as shown by:
- •a. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <2.5xULN (or <5 if hepatic metastases are present)
- •b. Total serum bilirubin <1.5xULN (<3xULN for patients known to have Gilberts Syndrome)
- •12. Adequate renal function as shown by:
- •a. Serum creatinine < 1.5xULN
- •b. Creatinine clearance ?50 ml/minute
- •13. Fasting serum cholesterol <300 mg/dL or 7.75 mmol/L and fasting triglycerides <2.5 x ULN.
- •14. ECOG Performance Status <2
- •15. Life expectancy >3 months
- •16. Loco-regional treatment (radiation, surgery) of one or more sites is allowed, as long as there are more non-treated sites prior to initiation of study treatment.
- •17. Ability to take oral medication and to comply with the study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 53
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 53
排除标准
- •1. Patients with only non-measurable lesions other than bone metastasis as define above (e.g., pleural effusion, ascites, etc).
- •2. Patients who have received prior hormonal or any other systemic therapy for metastatic / advanced breast cancer.
- •3. HER-2 positive and triple-negative breast cancer. A first metastatic relapse event that is limited to a single site and has been treated with radical intention (surgery, radiation therapy, etc.) constitutes an exclusion criteria, including single-site brain metastasis.
- •4. Previous treatment with mTOR inhibitors.
- •5. Known hypersensitivity to mTOR inhibitors, e.g., sirolimus (rapamycin), everolimus or letrozole.
- •6. Neoadjuvant or adjuvant treatment termination due to intolerance to letrozole.
- •7. Lack of paraffin tumor sample from the initial breast cancer diagnosis. Patient is not eligible if only a post-neoadjuvant treatment sample is available.
- •8. Another malignancy within 5 years prior to enrollment with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer
- •9. Radiotherapy within four weeks prior to enrollment except in case of localized radiotherapy for analgesic purpose of lytic lesions at risk of fracture which can then be completed within two weeks prior to enrollment.
- •10. Currently receiving hormone replacement therapy, unless discontinued prior to enrollment
- •11. Patients receiving concomitant immunosuppressive agents or chronic corticosteroids use, at the time of study entry except in cases outlined below: Prolonged systemic corticosteroid treatment during study, except for topical applications (e.g. rash),inhaled sprays (e.g. obstructive airways diseases), eye drops or local injections (e.g. intraarticular) should not be given. However, during the study:
- •? short duration (<2 weeks) of systemic corticosteroids is allowed (e.g. chronic obstructive pulmonary disease, anti-emetic);
- •? low doses of corticosteroids for brain metastasis treatment is allowed.
- •12. Bilateral diffuse lymphangitic carcinomatosis.
- •13. Patients with a known history of HIV seropositivity. Screening for HIV infection at baseline is not required.
- •14. Active bleeding diathesis.
- •15. Any severe and/or uncontrolled medical conditions such as:
- •a. Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction <6 months prior to enrollment, serious uncontrolled cardiac arrhythmia.
- •b. Uncontrolled diabetes as defined by fasting serum glucose >1.5xULN.
- •c. Impairment of gastrointestinal function or who have gastrointestinal disease that may significantly alter the absorption of study drugs (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
- •d. Active skin, mucosa, ocular or GI disorders of Grade >1
- •e. Uncontrolled Chronic Obstructive Pulmonary Disease
- •f. Severe mental impairment
- •h. Acute and chronic, active infectious disorders (except for Hep B and Hep C positive patients) and nonmalignant medical illness that are uncontrolled or whose control may be jeopardized by the complications of this study therapy
- •i. Any other severe condition that according to the investigator could interfere with the administration of the study treatment.
- •16. Patients who have undergone major surgery within 4 weeks prior to starting study drug (e.g., intra-thoracic, intra-abdominal, or intra-pelvic).
- •17. Significant symptomatic deterioration of lung function. If clinically indicated, pulmonary fu
研究者
相似试验
已完成
2 期
A Phase 2a study to evaluate the Efficacy, Safety, and Tolerability of MORF-057 in Ulcerative Colitis2024-516960-27-00Morphic Therapeutic Inc.31
撤回
2 期
A Phase 2, Open-label, Single-arm Study to Evaluate the Tolerability, Safety, and Pharmacodynamic Effects of KER-012 in Participants with Chronic Heart Failure.Cardiovascular - Other cardiovascular diseasesChronic Heart FailureACTRN12623001290684Keros Therapeutics, Inc.12
已完成
2 期
A single arm, phase II, open-label study to determine the efficacy of 100mg twice daily oral dosing of Midostaurin administered to patients with Agressive Systemic Mastocytosis or Mast Cell Leukemia +/- an Associated Hematological Clonal Non-Mast Cell Lineage DiseaseAgressive Systemic Mastocytosis10024324NL-OMON37318ovartis3
进行中（未招募）
1 期
ADVANCE: A clinical study of Atezolizumab and Derazantinib for patients with advanced intrahepatic cholangiocarcinoma with gene FGFR2 fusions/rearrangementsAdvanced non-resectable intrahepatic cholangiocarcinoma with positively confirmed FGFR2 fusion/rearrangements via NGS-AnalysisMedDRA version: 27.0Level: PTClassification code 10008593Term: CholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 27.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 27.0Level: LLTClassification code 10073077Term: Intrahepatic cholangiocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 27.0Level: LLTClassification code 10077846Term: Cholangiocarcinoma metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-004938-38-DEFrankfurter Institut für Klinische Krebsforschung IKF GmbH27
进行中（未招募）
1 期
A single arm, Phase II, Open-label Study to determine the efficacy of 100 mg twice daily oral dosing of midostaurin administered to patients with Agressive Systemic Mastocytosis or Mast Cell Leukemia +/- an associated hematological clonal non-mast cell lineage disease - CPKC412D2201Agressive Systemic Mastocytosis (ASM) or Mast Cell Leukemia (MCL) +/- an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)MedDRA version: 9.1Level: LLTClassification code 10056453Term: Aggressive systemic mastocytosisEUCTR2008-000280-42-FRovartis Pharma Services AG60